The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
How ERAP1 and ERAP2 shape the peptidomes of disease-associated MHC-I proteins
JA López de Castro - Frontiers in Immunology, 2018 - frontiersin.org
Four inflammatory diseases are strongly associated with Major Histocompatibility Complex
class I (MHC-I) molecules: birdshot chorioretinopathy (HLA-A* 29: 02), ankylosing …
class I (MHC-I) molecules: birdshot chorioretinopathy (HLA-A* 29: 02), ankylosing …
Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice
X Liu, S Jiang, C Fang, S Yang, D Olalere… - Cancer research, 2015 - AACR
Target-mediated toxicity is a major limitation in the development of chimeric antigen T-cell
receptors (CAR) for adoptive cell therapy of solid tumors. In this study, we developed a …
receptors (CAR) for adoptive cell therapy of solid tumors. In this study, we developed a …
Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy
Q Zhang, W Wei, P Wang, L Zuo, F Li, J Xu, X Xi… - ACS …, 2017 - ACS Publications
Adoptive T-cell transfer for cancer therapy relies on both effective ex vivo T-cell expansion
and in vivo targeting performance. One promising but challenging method for accomplishing …
and in vivo targeting performance. One promising but challenging method for accomplishing …
A carbon nanotube–polymer composite for T-cell therapy
Clinical translation of cell therapies requires strategies that can manufacture cells efficiently
and economically. One promising way to reproducibly expand T cells for cancer therapy is …
and economically. One promising way to reproducibly expand T cells for cancer therapy is …
Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time
T cell receptor (TCR) binding to diverse peptide-major histocompatibility complex (pMHC)
ligands results in various degrees of T cell activation. Here we analyze which binding …
ligands results in various degrees of T cell activation. Here we analyze which binding …
Phenotypic models of T cell activation
M Lever, PK Maini, PA Van Der Merwe… - Nature Reviews …, 2014 - nature.com
T cell activation is a crucial checkpoint in adaptive immunity, and this activation depends on
the binding parameters that govern the interactions between T cell receptors (TCRs) and …
the binding parameters that govern the interactions between T cell receptors (TCRs) and …
The quest for the best: how TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses
Over the past decades, adoptive transfer of T cells has revolutionized cancer
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
SE James, PD Greenberg, MC Jensen… - The Journal of …, 2008 - journals.aai.org
We have targeted CD22 as a novel tumor-associated Ag for recognition by human CTL
genetically modified to express chimeric TCR (cTCR) recognizing this surface molecule …
genetically modified to express chimeric TCR (cTCR) recognizing this surface molecule …
DNA origami demonstrate the unique stimulatory power of single pMHCs as T-cell antigens
T-cells detect with their T-cell antigen receptors (TCRs) the presence of rare agonist
peptide/MHC complexes (pMHCs) on the surface of antigen presenting cells (APCs). How …
peptide/MHC complexes (pMHCs) on the surface of antigen presenting cells (APCs). How …